FDA approves Navidea Lymphoseek injection for use in lymphatic mapping Navidea Biopharmaceuticals (NAVB) announced U.S. Food and Drug Administration approval of Lymphoseek Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek will be sold and distributed in the U.S. on an exclusive basis by Cardinal Health (CAH).
News For NAVB;CAH From The Last 14 Days
Check below for free stories on NAVB;CAH the last two weeks.
Navidea initiates NAV5001 SPECT Phase 3 registration program Navidea Biopharmaceuticals announced the first subject has been enrolled in one of the two planned NAV5001 Phase 3 clinical trials. The trial will assess the safety and efficacy of NAV5001, an investigational imaging agent as an aid in the differential diagnosis of Parkinsonian Syndromes from non-Parkinsonian tremor. NAV5001 is an investigational imaging agent used to visualize dopamine transporter protein located on the nigrostriatal neurons in the brain using single photon emission tomography imaging.